55293-96-4

Basic information

• Product Name: [1,2,4]Triazolo[1,5-a]pyriMidine-2-carboxaldehyde, 5,7-diMethyl-
• Synonyms: [1,2,4]Triazolo[1,5-a]pyriMidine-2-carboxaldehyde, 5,7-diMethyl-
• CAS NO: 55293-96-4
• Molecular Formula: C₈H₈N₄O
• Molecular Weight: 176.17532
• EINECS: -0
• Mol File: 55293-96-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: [1,2,4]Triazolo[1,5-a]pyriMidine-2-carboxaldehyde, 5,7-diMethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: [1,2,4]Triazolo[1,5-a]pyriMidine-2-carboxaldehyde, 5,7-diMethyl-(55293-96-4)
• EPA Substance Registry System: [1,2,4]Triazolo[1,5-a]pyriMidine-2-carboxaldehyde, 5,7-diMethyl-(55293-96-4)

Safety Data

• Hazardous Substances Data: 55293-96-4(Hazardous Substances Data)

Usage

General Description

[1,2,4]Triazolo[1,5-a]pyrimidine-2-carboxaldehyde, 5,7-dimethyl- is a chemical compound with the molecular formula C10H11N5O. It is a pyrimidine derivative with a triazolo ring and a carboxaldehyde functional group. [1,2,4]Triazolo[1,5-a]pyrimidine-2-carboxaldehyde, 5,7-dimethyl- is often used in the synthesis of various pharmaceuticals and organic compounds due to its unique molecular structure and the presence of the carboxaldehyde group, which makes it a versatile building block for the preparation of diverse chemical entities. Additionally, its 5,7-dimethyl substituents contribute to its stability and chemical reactivity, making it a valuable intermediate in organic synthesis and medicinal chemistry.

Upstream product

• 1508308-97-1 C₂₉H₃₆⁽²⁾HN₅O₃ 
• 63870-39-3 (5-amino-1H-[1,2,4]triazol-3-yl)-methanol; glycolate 
• 54535-00-1 (5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methanol 

Downstream Products

• 877130-28-4 filibuvir 
• 1228897-40-2 C₂₉H₃₅N₅O₃ 
• 749931-52-0 C₂₇H₃₁ClN₄O₄ 
• 1269149-94-1 C₃₀H₃₄ClN₅O₃ 
• 1026170-39-7 C₂₉H₃₅ClN₄O₄ 
• 1269149-79-2 C₂₉H₃₄N₄O₆ 
• 1269149-81-6 C₃₀H₃₅ClN₄O₅ 
• 1269149-84-9 methyl 4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4,6-dioxotetrahydro-2H-pyran-2-yl}ethyl)-2-fluorobenzoate 
• 1269149-85-0 C₂₉H₃₅ClN₄O₄ 
• 1269149-92-9 C₃₀H₃₉N₅O₅S 
• 1269149-95-2 C₃₂H₃₇N₅O₅ 
• 1508308-99-3 C₅₀H₆₄N₆O₆ 
• 54535-00-1 (5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methanol 
• 901735-11-3 3-(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)propanoic acid 

Relevant articles and documents

Synthesis of filibuvir. Part III. Development of a process for the reductive coupling of an aldehyde and a β-keto-lactone

Development of a reductive coupling of a β-keto-lactone and an aldehyde is described, in which the Hantzsch ester serves as an inexpensive and convenient reducing agent. Structural features in the β-keto-lactone rendered standard reductive coupling conditions ineffective, requiring development of a specific addition and temperature protocol. Identification of one of the reactants as Ames positive required a single-digit parts per million control strategy for this impurity in the final active pharmaceutical ingredient (API).

METHODS FOR THE PREPARATION OF HCV POLYMERASE INHIBITORS

The present invention relates to methods and compounds useful in the preparation of compounds of the formula (I).

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).